(MedPage Today) — An antidiabetic mainstay did not provide an additional survival benefit to patients with metastatic hormone-sensitive prostate cancer, according to results from a phase III trial.
In STAMPEDE, overall survival was not statistically…
Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/116425
Author :
Publish date : 2025-07-08 21:39:00
Copyright for syndicated content belongs to the linked Source.
